Article
Gastroenterology & Hepatology
Nadiye Akdeniz, Muhammet Ali Kaplan, Dogan Uncu, Mevlude Inanc, Serap Kaya, Faysal Dane, Mehmet Kucukoner, Ayse Demirci, Mehmet Bilici, Ayse Gok Durnali, Lokman Koral, Mehmet Ali Nahit Sendur, Cihan Erol, Esma Turkmen, Omer Fatih Olmez, Ozgur Acikgoz, Sahin Lacin, Hayriye Sahinli, Zuhat Urakci, Abdurrahman Isikdogan
Summary: In adjuvant treatment for stage III colorectal cancer patients, three different 5-FU administration types in FOLFOX combination therapy demonstrate similar efficacy and manageable toxicity. There were no statistically significant differences in DFS and OS among the three treatment groups.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Article
Genetics & Heredity
Fangzhou Li, Fen Qiu, Xu Fan, Qingqing Yu, Shuaitong Liu, Yang Guo, Yunhe Zhu, Xueyan Xi, Boyu Du
Summary: The development of chemoresistance in colorectal cancer cells is mainly attributed to the existence of cancer stem cells. This study found that the expression of ELF3 gene is associated with the increase of CD44, and inhibiting ELF3 can decrease CD44 expression. ELF3 is significantly higher in CD44+ colorectal cancer cells.
Article
Oncology
Fei Yao, Xiaoying Huang, Zhufu Xie, Jie Chen, Ling Zhang, Qiang Wang, Hui Long, Jue Jiang, Qingming Wu
Summary: This study identified the important role of LINC02418/miR-372-3p/EPHA2 in the chemoresistance of colorectal cancer (CRC), providing potential therapeutic targets for improving chemosensitivity.
Article
Oncology
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Marco Maria Germani, Giulia Barsotti, Vincenzo Formica, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Lorenzo Antonuzzo, Carlotta Antoniotti, Margherita Ambrosini, Vittoria Matilde Piva, Federico Nichetti, Matteo Fassan, Chiara Cremolini, Sara Lonardi
Summary: Upfront anti-EGFR therapy is the standard treatment for elderly patients with specific types of colorectal cancer. Comprehensive genomic profiling can help identify patients with resistance alterations, whose outcomes are worse compared to patients without these alterations.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Shenshen Wu, Xi Yang, Weiyan Tang, Giuseppe Familiari, Michela Relucenti, Michael Aschner, Xiaobo Li, Rui Chen
Summary: Recent studies have found an association between the PVT1 rs2278176 CT/TT genotypes and a better chemotherapy response, overall survival, and progression-free survival in metastatic colorectal cancer patients. In vivo experiments showed that the rs2278176 C to T mutation inhibited tumor growth and increased apoptosis in colorectal cancer cells treated with 5-Fu. Functional studies revealed that the rs2278176 C to T mutation altered the binding site for hsa-miR-297, leading to downregulation of GSTA2 expression. High GSTA2 expression predicted poor clinical outcomes in metastatic colorectal cancer treated with FOLFOX.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Medicinal
Dongdong Luo, Xiaochun Liu, Leilei Jiang, Zhikun Guo, Yan Lv, Xiaochen Tian, Xiaoyan Wang, Shuxiang Cui, Shengbiao Wan, Xianjun Qu, Ximing Xu, Xiaoyang Li
Summary: In this study, 38 novel S1PR2 antagonists were synthesized and their structure-activity relationship investigated. Compound 43 showed the strongest interaction with S1PR2 and exhibited potent 5-FU resensitizing activity in 5-FU-resistant tumor cells.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Medicine, Research & Experimental
Elham Fakhr, Fatemeh Zare, Kayhan Azadmanesh, Ladan Teimoori-Toolabi
Summary: LEF1 plays an important role in the chemo-resistance of colorectal cancer cells, with downregulation of the long isoform making cells more sensitive to chemotherapy through reduced proliferation, increased apoptosis, or cell cycle arrest. Balancing the expression of long and short isoforms of LEF1 is crucial in overcoming chemo-resistance.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Gui-Li Zheng, Yu-Lin Liu, Ze-Xuan Yan, Xiao-Ye Xie, Zhuo Xiang, Li Yin, Qing-Qing Wang, Dao-Chen Chong, Guo-Liang Xue, Li-Li Xu, Kai Zhou, Qiang Wang
Summary: Elevated expression of LINC01347 is associated with disease progression and poor prognosis in colorectal cancer (CRC) patients undergoing chemotherapy. LINC01347 may play a role in promoting cell proliferation and resistance to 5-FU in CRC cells, potentially through regulation of LOXL2 via miR-328-5p. Identification of LINC01347 as a prognostic biomarker and therapeutic target highlights its potential in overcoming chemotherapy resistance in CRC.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Cecile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, Violaine Randrian, Solene Doat, Cindy Neuzillet, Valerie Moulin, Morgane Stouvenot, Gael Roth, Tiffany Darbas, Benjamin Auberger, Tiphaine Godet, Marion Jaffrelot, Aurelien Lambert, Olivier Dubreuil, Cassandre Gluszak, Alice Bernard-Tessier, Anthony Turpin, Lola-Jade Palmieri, Olivier Bouche, Gael Goujon, Thierry Lecomte, David Sefrioui, Christophe Locher, Lucien Grados, Pauline Gignoux, Stephanie Trager, Elise Nassif, Angelique Saint, Pascal Hammel, Cedric Lecaille, Mathilde Bureau, Marine Perrier, Damien Botsen, Vincent Bourgeois, Julien Taieb, Edouard Auclin
Summary: In second-line treatment, for patients with metastatic colorectal cancer, the combination of FOLFIRI and bevacizumab is associated with longer overall survival and progression-free survival compared to the combination of FOLFIRI and aflibercept.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Ninon Very, Stephan Hardiville, Amelie Decourcelle, Julien Thevenet, Madjid Djouina, Adeline Page, Gerard Vergoten, Celine Schulz, Julie Kerr-Conte, Tony Lefebvre, Vanessa Dehennaut, Ikram El Yazidi-Belkoura
Summary: Alteration of O-GlcNAcylation affects tumorigenesis and tumor progression, with a potential role in chemotherapy response. Combination treatment of 5-FU with Thiamet-G shows synergistic inhibitory effects on CRC progression by regulating TS and O-GlcNacylation levels. Overall, the findings suggest a new approach to enhance CRC response to 5-FU chemotherapy by targeting O-GlcNAcylation.
Article
Oncology
Yaoqing Li, Chuchu Xu, Renjun Zhu, Liyijing Shen, Gengyuan Hu, Kelong Tao, Feng Tao, Zengxin Lu, Guolin Zhang
Summary: This study evaluates the value of tissue inhibitors of MMPs-2 (TIMP-2) as an indicator of 5-Fluorouracil (5-Fu) resistance in colorectal cancer. The results show that TIMP-2 expression is elevated in drug-resistant colorectal cancer cell lines and is closely related to 5-Fu resistance. Monitoring serum TIMP-2 levels can help clinicians identify 5-Fu resistance in colorectal cancer patients earlier during chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Yu Wang, Haihong Hu, Lushan Yu, Su Zeng
Summary: The purpose of this study was to establish physiologically based pharmacokinetic (PBPK) models of capecitabine-metabolites and 5-FU-metabolites to describe their pharmacokinetics in tumor and plasma of cancer patients with liver impairment. The models were successfully constructed and validated using data from cancer patients. The models showed that tumor blood flow rate is critical for 5-FU concentration in tumor, and dosage adaptation of capecitabine or 5-FU is not required for cancer patients with hepatic impairment.
PHARMACEUTICAL RESEARCH
(2023)
Article
Pathology
Yu-Ling Qu, Xiao-Li Liu, Shan-Yu Zhao, Xue-Feng Zhai
Summary: This study found that SPOCK1 is upregulated in 5-FU-resistant CRC cells and that knockdown of SPOCK1 increases their sensitivity to 5-FU. Conversely, overexpression of SPOCK1 enhances CRC cell resistance to 5-FU and reduces cell apoptosis.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Oncology
Zhiqiang Tong, Mengfei Cheng, Yang Yu, Jiuhang Yu, Yichuang Yin, Jiahui Liu, Shuo Zhang, Shuai Jiang, Mei Dong
Summary: This study investigated the AUC range and correlation between 5-FU metabolites concentration and adverse reactions in patients with advanced CRC receiving 5-FU-based chemotherapy. The results showed significant individual differences in AUC values, and a significant correlation between 5-FUH2 and FABL concentration and adverse reactions.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
Robert A. Nagourney, Steven Evans, Peter H. Tran, Adam J. Nagourney, Paul H. Sugarbaker
Summary: Patients with colon cancer who have received specific drug treatments are more likely to exhibit resistance to oxaliplatin, reducing the efficacy of heated intraperitoneal chemotherapy (HIPEC).
Letter
Oncology
Liz J. Hernandez Borrero, Rahmat Sikder, Amriti Lulla, Prashanth Gokare, Paulo R. Del Valle, Xiaobing Tian, Shengliang Zhang, Philip H. Abbosh, Wafik S. El-Deiry
Article
Cell Biology
Liz J. Hernandez-Borrero, Shengliang Zhang, Amriti Lulla, David T. Dicker, Wafik S. El-Deiry
Article
Cell Biology
Varun V. Prabhu, Mala K. Talekar, Amriti R. Lulla, C. Leah B. Kline, Lanlan Zhou, Junior Hall, A. Pieter J. Van den Heuvel, David T. Dicker, Jawad Babar, Stephan A. Grupp, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Jeffrey J. Pu, David F. Claxton, Nadia Khan, Wolfgang Oster, Joshua E. Allen, Wafik S. El-Deiry
Review
Biochemistry & Molecular Biology
Lorenzo Galluzzi, Ilio Vitale, Stuart A. Aaronson, John M. Abrams, Dieter Adam, Patrizia Agostinis, Emad S. Alnemri, Lucia Altucci, Ivano Amelio, David W. Andrews, Margherita Annicchiarico-Petruzzelli, Alexey V. Antonov, Eli Arama, Eric H. Baehrecke, Nickolai A. Barlev, Nicolas G. Bazan, Francesca Bernassola, Mathieu J. M. Bertrand, Katiuscia Bianchi, Mikhail V. Blagosklonny, Klas Blomgren, Christoph Borner, Patricia Boya, Catherine Brenner, Michelangelo Campanella, Eleonora Candi, Didac Carmona-Gutierrez, Francesco Cecconi, Francis K. -M. Chan, Navdeep S. Chandel, Emily H. Cheng, Jerry E. Chipuk, John A. Cidlowski, Aaron Ciechanover, Gerald M. Cohen, Marcus Conrad, Juan R. Cubillos-Ruiz, Peter E. Czabotar, Vincenzo D'Angiolella, Ted M. Dawson, Valina L. Dawson, Vincenzo De laurenzi, Ruggero De Maria, Klaus-Michael Debatin, Ralph J. DeBerardinis, Mohanish Deshmukh, Nicola Di Daniele, Francesco Di Virgilio, Vishva M. Dixit, Scott J. Dixon, Colin S. Duckett, Brian D. Dynlacht, Wafik S. El-Deiry, John W. Elrod, Gian Maria Fimia, Simone Fulda, Ana J. Garcia-Saez, Abhishek D. Garg, Carmen Garrido, Evripidis Gavathiotis, Pierre Golstein, Eyal Gottlieb, Douglas R. Green, Lloyd A. Greene, Hinrich Gronemeyer, Atan Gross, Gyorgy Hajnoczky, J. Marie Hardwick, Isaac S. Harris, Michael O. Hengartner, Claudio Hetz, Hidenori Ichijo, Marja Jaattela, Bertrand Joseph, Philipp J. Jost, Philippe P. Juin, William J. Kaiser, Michael Karin, Thomas Kaufmann, Oliver Kepp, Adi Kimchi, Richard N. Kitsis, Daniel J. Klionsky, Richard A. Knight, Sharad Kumar, Sam W. Lee, John J. Lemasters, Beth Levine, Andreas Linkermann, Stuart A. Lipton, Richard A. Lockshin, Carlos Lopez-Otin, Scott W. Lowe, Tom Luedde, Enrico Lugli, Marion MacFarlane, Frank Madeo, Michal Malewicz, Walter Malorni, Gwenola Manic, Jean-Christophe Marine, Seamus J. Martin, Jean-Claude Martinou, Jan Paul Medema, Patrick Mehlen, Pascal Meier, Sonia Melino, Edward A. Miao, Jeffery D. Molkentin, Ute M. Moll, Cristina Munoz-Pinedo, Shigekazu Nagata, Gabriel Nunez, Andrew Oberst, Moshe Oren, Michael Overholtzer, Michele Pagano, Theocharis Panaretakis, Manolis Pasparakis, Josef M. Penninger, David M. Pereira, Shazib Pervaiz, Marcus E. Peter, Mauro Piacentini, Paolo Pinton, Jochen H. M. Prehn, Hamsa Puthalakath, Gabriel A. Rabinovich, Markus Rehm, Rosario Rizzuto, Cecilia M. P. Rodrigues, David C. Rubinsztein, Thomas Rudel, Kevin M. Ryan, Emre Sayan, Luca Scorrano, Feng Shao, Yufang Shi, John Silke, Hans-Uwe Simon, Antonella Sistigu, Brent R. Stockwell, Andreas Strasser, Gyorgy Szabadkai, Stephen W. G. Tait, Daolin Tang, Nektarios Tavernarakis, Andrew Thorburn, Yoshihide Tsujimoto, Boris Turk, Tom Vanden Berghe, Peter Vandenabeele, Matthew G. Vander Heiden, Andreas Villunger, Herbert W. Virgin, Karen H. Vousden, Domagoj Vucic, Erwin F. Wagner, Henning Walczak, David Wallach, Ying Wang, James A. Wells, Will Wood, Junying Yuan, Zahra Zakeri, Boris Zhivotovsky, Laurence Zitvogel, Gerry Melino, Guido Kroemer
CELL DEATH AND DIFFERENTIATION
(2018)
Article
Medicine, Research & Experimental
Jessica Wagner, C. Leah Kline, Lanlan Zhou, Kerry S. Campbell, Alexander W. MacFarlane, Anthony J. Olszanski, Kathy Q. Cai, Harvey H. Hensley, Eric A. Ross, Marie D. Ralff, Andrew Zloza, Charles B. Chesson, Jenna H. Newman, Howard Kaufman, Joseph Bertino, Mark Stein, Wafik S. El-Deiry
JOURNAL OF CLINICAL INVESTIGATION
(2018)
Article
Oncology
Jessica Wagner, C. Leah Kline, Lanlan Zhou, Vladimir Khazak, Wafik S. El-Deiry
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2018)
Article
Oncology
Avital Lev, Amriti R. Lulla, Brian C. Ross, Marie D. Ralff, Petr B. Makhov, David T. Dicker, Wafik S. El-Deiry
MOLECULAR CANCER RESEARCH
(2018)
Article
Medicine, General & Internal
A. Drilon, T. W. Laetsch, S. Kummar, S. G. DuBois, U. N. Lassen, G. D. Demetri, M. Nathenson, R. C. Doebele, A. F. Farago, A. S. Pappo, B. Turpin, A. Dowlati, M. S. Brose, L. Mascarenhas, N. Federman, J. Berlin, W. S. El-Deiry, C. Baik, J. Deeken, V. Boni, R. Nagasubramanian, M. Taylor, E. R. Rudzinski, F. Meric-Bernstam, D. P. S. Sohal, P. C. Ma, L. E. Raez, J. F. Hechtman, R. Benayed, M. Ladanyi, B. B. Tuch, K. Ebata, S. Cruickshank, N. C. Ku, M. C. Cox, D. S. Hawkins, D. S. Hong, D. M. Hyman
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Oncology
Elizabeth M. Matthew, Zhaohai Yang, Suraj Peri, Mark Andrake, Roland Dunbrack, Eric Ross, Wafik S. El-Deiry
Article
Oncology
Christina Leah B. Kline, Marie D. Ralff, Amriti R. Lulla, Jessica M. Wagner, Phillip H. Abbosh, David T. Dicker, Joshua E. Allen, Wafik S. El-Deiry
Article
Multidisciplinary Sciences
Prashanth Gokare, Niklas K. Finnberg, Phillip H. Abbosh, Jenny Dai, Maureen E. Murphy, Wafik S. El-Deiry
SCIENTIFIC REPORTS
(2017)
Article
Oncology
Lindsey Carlsen, Kelsey E. Huntington, Wafik S. El-Deiry
Summary: This review discusses preclinical and clinical studies on immunotherapy for colorectal cancer, including various treatment methods and predictive biomarkers for treatment response. Despite certain limitations, immunotherapy provides hope for improving patient outcomes and quality of life.
Review
Biochemistry & Molecular Biology
Shengliang Zhang, Lindsey Carlsen, Liz Hernandez Borrero, Attila A. Seyhan, Xiaobing Tian, Wafik S. El-Deiry
Summary: This article summarizes the current progress in targeting wild-type and mutant p53 for cancer therapy using biotherapeutic and biopharmaceutical methods. Strategies include boosting p53 activity, restoring p53 pathway function, targeting p53 in immunotherapy, and combination therapies.
Review
Biochemistry & Molecular Biology
Lindsey Carlsen, Wafik S. El-Deiry
Summary: The TP53 gene, encoding the tumor suppressor protein p53, is mutated in around 50% of cancers. After DNA damage, p53 acts as a transcription factor to activate target genes for cell fates such as apoptosis, cell cycle arrest, and DNA repair. The complex regulatory network controlling target gene selection by p53 varies across contexts such as treatment type, cell type, and tissue type.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Colby Richardson, Shengliang Zhang, Liz J. Hernandez Borrero, Wafik S. El-Deiry